Moleculin Biotech, Inc. 8-K

What Happened Moleculin Biotech, Inc. announced that Nasdaq’s Listing Qualifications Staff informed the Nasdaq hearing Panel on January 6, 2026 that the company has regained compliance with Nasdaq Listing Rule 5550(b)(1) and is in compliance with all applicable continued listing standards. The company had previously been notified on May 23, 2025 that it did not meet the Listing Rule (minimum $2.5 million in stockholders’ equity) and received a delist determination on November 20, 2025; Moleculin had requested a hearing with the Panel. With Nasdaq’s notice of regained compliance, the scheduled hearing was canceled.

Key Details

• Nasdaq Listing Rule involved: Rule 5550(b)(1) (minimum $2.5 million in stockholders’ equity).
• Initial non-compliance notice received: May 23, 2025.
• Delist determination issued by Nasdaq Staff: November 20, 2025; company requested a Panel hearing.
• Nasdaq Staff informed the Panel the company had regained compliance on January 6, 2026, and the hearing was canceled.

Why It Matters This filing confirms Moleculin has met Nasdaq’s listing standards again, avoiding a possible delisting process. For investors, regained compliance preserves the company’s continued listing on Nasdaq, maintaining market liquidity and avoiding the operational and reputational impacts that can accompany delisting proceedings.